HLB Pharmaceutical (A047920) Stock Overview
Researches and develops peptide drugs in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A047920 from our risk checks.
A047920 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
HLB Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩17,690.00 |
| 52 Week High | ₩22,250.00 |
| 52 Week Low | ₩12,500.00 |
| Beta | 0.39 |
| 1 Month Change | 8.86% |
| 3 Month Change | -11.51% |
| 1 Year Change | -9.38% |
| 3 Year Change | 19.53% |
| 5 Year Change | 13.40% |
| Change since IPO | 121.13% |
Recent News & Updates
Shareholder Returns
| A047920 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -1.1% | -0.4% | 6.1% |
| 1Y | -9.4% | 43.8% | 149.0% |
Return vs Industry: A047920 underperformed the KR Pharmaceuticals industry which returned 43.8% over the past year.
Return vs Market: A047920 underperformed the KR Market which returned 149% over the past year.
Price Volatility
| A047920 volatility | |
|---|---|
| A047920 Average Weekly Movement | 8.3% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in KR Market | 16.2% |
| 10% least volatile stocks in KR Market | 4.7% |
Stable Share Price: A047920 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A047920's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Jae-Hyung Park | www.hlbpharma.co.kr |
HLB Pharmaceutical Co., Ltd. researches and develops peptide drugs in South Korea. The company offers skeletal muscle relaxant, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, antidiabetic drug, chemotherapeutics, peptic ulcer agents, central nervous system drug, antibiotics, digestives, antacids, dental drugs, multivitamins, parasistic skin disese drugs, dermatlogicals, agents for urogenital organ, amino acid agent, antitussive, mucolytic agents, anthelmintics, antidiarrheals, circulatory system drug, vitamins, skin softeners, anti-hemorrhoid drugs, and agents for liver disease. It is also developing CTT-004 for the treatment of ataxia induced by spinocerebellar degeneration; and offers CMO services.
HLB Pharmaceutical Co., Ltd. Fundamentals Summary
| A047920 fundamental statistics | |
|---|---|
| Market cap | ₩248.41b |
| Earnings (TTM) | ₩4.57b |
| Revenue (TTM) | ₩205.58b |
Is A047920 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A047920 income statement (TTM) | |
|---|---|
| Revenue | ₩205.58b |
| Cost of Revenue | ₩99.17b |
| Gross Profit | ₩106.42b |
| Other Expenses | ₩101.84b |
| Earnings | ₩4.57b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 325.57 |
| Gross Margin | 51.76% |
| Net Profit Margin | 2.22% |
| Debt/Equity Ratio | 12.0% |
How did A047920 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/28 00:35 |
| End of Day Share Price | 2026/04/28 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HLB Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.